CN112469409B - 用于治疗疾病状态和病症的对映异构体纯的gper激动剂 - Google Patents

用于治疗疾病状态和病症的对映异构体纯的gper激动剂

Info

Publication number
CN112469409B
CN112469409B CN201980048925.4A CN201980048925A CN112469409B CN 112469409 B CN112469409 B CN 112469409B CN 201980048925 A CN201980048925 A CN 201980048925A CN 112469409 B CN112469409 B CN 112469409B
Authority
CN
China
Prior art keywords
srr
derivative
compound
acid
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980048925.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN112469409A (zh
Inventor
C.纳塔尔
P.穆尼
T.加里安特斯
W.卢克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Linnai Medical Co ltd
Original Assignee
Linnai Medical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Linnai Medical Co ltd filed Critical Linnai Medical Co ltd
Publication of CN112469409A publication Critical patent/CN112469409A/zh
Application granted granted Critical
Publication of CN112469409B publication Critical patent/CN112469409B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/19—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
    • C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
    • C07C309/35—Naphthalene sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201980048925.4A 2018-07-21 2019-07-22 用于治疗疾病状态和病症的对映异构体纯的gper激动剂 Active CN112469409B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862701726P 2018-07-21 2018-07-21
US62/701,726 2018-07-21
PCT/US2019/042827 WO2020023391A1 (en) 2018-07-21 2019-07-22 Enantiomerically purified gper agonist for use in treating disease states and conditions

Publications (2)

Publication Number Publication Date
CN112469409A CN112469409A (zh) 2021-03-09
CN112469409B true CN112469409B (zh) 2026-03-13

Family

ID=69160978

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980048925.4A Active CN112469409B (zh) 2018-07-21 2019-07-22 用于治疗疾病状态和病症的对映异构体纯的gper激动剂

Country Status (23)

Country Link
US (6) US20200024262A1 (https=)
EP (2) EP3823617B1 (https=)
JP (2) JP2021532148A (https=)
KR (1) KR20210049778A (https=)
CN (1) CN112469409B (https=)
AU (1) AU2019310029B2 (https=)
BR (1) BR112021001031A2 (https=)
CA (1) CA3107109A1 (https=)
DK (1) DK3823617T3 (https=)
ES (1) ES2980434T3 (https=)
FI (1) FI3823617T3 (https=)
HR (1) HRP20240661T1 (https=)
HU (1) HUE067185T2 (https=)
IL (2) IL312938A (https=)
LT (1) LT3823617T (https=)
MX (2) MX2021000809A (https=)
NZ (1) NZ771952A (https=)
PL (1) PL3823617T3 (https=)
PT (1) PT3823617T (https=)
RS (1) RS65599B1 (https=)
SI (1) SI3823617T1 (https=)
SM (1) SMT202400205T1 (https=)
WO (1) WO2020023391A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022091029A1 (en) * 2020-10-30 2022-05-05 Resverlogix Corp. Methods for lowering hba1c level with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor
US20240376547A1 (en) * 2021-04-08 2024-11-14 Linnaeus Therapeutics, Inc. Oncologic variations associated with cancer and methods of treatment
WO2022245899A2 (en) * 2021-05-19 2022-11-24 Linaeus Therapeutics, Inc. Diagnostic methods and compositions for treatment of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8487100B2 (en) * 2005-08-04 2013-07-16 Stc.Unm Compounds for binding to ER alpha/beta and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US251870A (en) * 1882-01-03 Automatic gate
US6809104B2 (en) * 2001-05-04 2004-10-26 Tularik Inc. Fused heterocyclic compounds
WO2008153945A2 (en) * 2007-06-06 2008-12-18 University Of South Florida Nutraceutical co-crystal compositions
MX382354B (es) * 2010-11-01 2025-03-13 Celgene Car Llc Compuestos heterocíclicos y usos de los mismos.
US10251870B2 (en) * 2015-03-06 2019-04-09 Stc.Unm Method for treating obesity, diabetes, cardiovascular and kidney diseases by regulating GPR30/GPER activity
AU2016246688B2 (en) * 2015-04-06 2020-11-12 The Trustees Of The University Of Pennsylvania Compositions and methods for decreasing, or preventing or reversing gain of, skin pigmentation in a mammalian subject
US11369618B2 (en) 2016-06-17 2022-06-28 The Trustees Of The University Of Pennsylvania Compounds, compositions and methods for prevention and/or treatment of cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8487100B2 (en) * 2005-08-04 2013-07-16 Stc.Unm Compounds for binding to ER alpha/beta and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof

Also Published As

Publication number Publication date
EP4356913A2 (en) 2024-04-24
US20230382896A1 (en) 2023-11-30
HUE067185T2 (hu) 2024-10-28
SI3823617T1 (sl) 2024-09-30
HRP20240661T1 (hr) 2024-08-16
US20220089576A1 (en) 2022-03-24
JP2021532148A (ja) 2021-11-25
MX2024008188A (es) 2024-07-19
NZ771952A (en) 2026-01-30
AU2019310029B2 (en) 2025-05-29
PL3823617T3 (pl) 2024-08-12
US20250171421A1 (en) 2025-05-29
RS65599B1 (sr) 2024-06-28
CN112469409A (zh) 2021-03-09
IL280283A (en) 2021-03-01
IL312938A (en) 2024-07-01
US11760749B2 (en) 2023-09-19
PT3823617T (pt) 2024-06-03
JP2024119868A (ja) 2024-09-03
US20200024262A1 (en) 2020-01-23
WO2020023391A1 (en) 2020-01-30
US20200140417A1 (en) 2020-05-07
EP3823617B1 (en) 2024-03-06
US20220033385A1 (en) 2022-02-03
DK3823617T3 (da) 2024-06-03
US10934277B2 (en) 2021-03-02
SMT202400205T1 (it) 2024-07-09
FI3823617T3 (fi) 2024-05-29
ES2980434T3 (es) 2024-10-01
AU2019310029A1 (en) 2021-02-04
LT3823617T (lt) 2024-07-10
MX2021000809A (es) 2021-06-15
BR112021001031A2 (pt) 2021-04-13
EP4356913A3 (en) 2024-06-26
CA3107109A1 (en) 2020-01-30
KR20210049778A (ko) 2021-05-06
IL280283B1 (en) 2024-06-01
EP3823617A1 (en) 2021-05-26
IL280283B2 (en) 2024-10-01
EP3823617A4 (en) 2022-04-20

Similar Documents

Publication Publication Date Title
KR102519922B1 (ko) 트리아졸로피리미딘 화합물의 결정질 형태
CN113614083B (zh) 咪唑酮基喹啉化合物及其治疗用途
CN111770914B (zh) 作为神经激肽-1受体拮抗剂的化合物及其用途
CN115666566A (zh) 用于免疫病况的治疗的mk2途径抑制剂的口服组合物
US20250171421A1 (en) Enantiomerically purified gper agonist for use in treating disease states and conditions
JP2015532287A (ja) Ｉｒｅ１の調節
TW201201815A (en) 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
JP2020515527A (ja) 置換イミダゾール塩系化合物、その調製方法、医薬組成物およびその応用
TWI863667B (zh) 用於治療疾病之磷酸肌醇3-激酶(pi3k)異位色烯酮抑制劑
US20240190904A1 (en) Heteroaryl compounds as inhibitors of RIP2 kinase, composition and application thereof
CN117003737A (zh) 取代的咪唑苯基甲酮类化合物及其衍生物和药物组合物
CN111615391B (zh) 比卡格韦的代谢物
TW202517253A (zh) Cdk2抑制劑及其用途
CN116969926A (zh) 三嗪酮类化合物及其衍生物和药物组合物
BR112018076443B1 (pt) Processo de preparação de formas cristalinas de um composto de triazolopirimidina
BR122024009277A2 (pt) Formas cristalinas de um composto de triazolopirimidina

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant